Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Cue Biopharma, Inc. (CUE : NSDQ)

• Company Description    Cue Biopharma, Inc. is an immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers and autoimmune disorders. Cue Biopharma, Inc. is headquartered in Cambridge, Massachusetts. Number of Employees: 41

• Price / Volume Information    Yesterday's Closing Price: $0.80 Daily Weekly Monthly 20 Day Moving Average: 303,411 shares Shares Outstanding: 75.35 (millions) Market Capitalization: $59.98 (millions) Beta: 1.43 52 Week High: $1.99 52 Week Low: $0.45 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 25.22% 20.53% 12 Week 4.46% -12.13% Year To Date -26.97% -31.61%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 40 GUEST STREET - BOSTON,MA 02135 USA ph: 617-949-2680 fax: - ir@cuebio.com http://www.cuebiopharma.com

• General Corporate Information    Officers Daniel R. Passeri - Chief Executive Officer and Director Kerri-Ann Millar - Chief Financial Officer Peter A. Kiener - Director Frederick Driscoll - Director Pamela Garzone - Director Peer Information Cue Biopharma, Inc. (CORR.) Cue Biopharma, Inc. (RSPI) Cue Biopharma, Inc. (CGXP) Cue Biopharma, Inc. (BGEN) Cue Biopharma, Inc. (GTBP) Cue Biopharma, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 22978P106 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/13/25 Share - Related Items Shares Outstanding: 75.35 Most Recent Split Date: (:1) Beta: 1.43 Market Capitalization: $59.98 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.13 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.60 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/13/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 7.48 Price/Cash Flow: - Price / Sales: 7.51 EPS Growth vs. Year Ago Period: 32.00% vs. Previous Quarter: -30.77% Sales Growth vs. Year Ago Period: -75.48% vs. Previous Quarter: -73.29% ROE 06/30/25 - - 03/31/25 - -228.43 12/31/24 - -172.12 ROA 06/30/25 - - 03/31/25 - -114.66 12/31/24 - -93.89 Current Ratio 06/30/25 - - 03/31/25 - 1.03 12/31/24 - 1.84 Quick Ratio 06/30/25 - - 03/31/25 - 1.03 12/31/24 - 1.84 Operating Margin 06/30/25 - - 03/31/25 - -507.87 12/31/24 - -437.97 Net Margin 06/30/25 - - 03/31/25 - -507.87 12/31/24 - -437.97 Pre-Tax Margin 06/30/25 - - 03/31/25 - -507.87 12/31/24 - -437.97 Book Value 06/30/25 - - 03/31/25 - 0.11 12/31/24 - 0.28 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©